TransCode Therapeutics study shows survival gains in breast cancer model
A new peer-reviewed study published in the journal Cancers demonstrates that TransCode Therapeutics’ lead candidate, TTX-MC138, significantly extended survival in preclinical models of breast cancer bone metastasis. The research validates the company's approach to inhibiting microRNA-10b, a key driver of cancer progression, using proprietary oligonucleotide nanotechnology.
The study, led by Dr. Anna Moore of Michigan State University, utilized an image-guided delivery system to concentrate TTX-MC138 in metastatic bone lesions. In the mouse model, the treatment successfully suppressed microRNA-10b expression while simultaneously increasing levels of HOXD10, a protein that functions as a tumor suppressor. Researchers observed no systemic toxicity during the trial, suggesting the therapeutic candidate is well-tolerated even with repeated dosing.
Zdravka Medarova, Chief Scientific Officer at TransCode, noted that these findings underscore the potential of miR-10b inhibition to address metastatic disease, which remains the primary cause of cancer-related mortality. While the company is currently evaluating TTX-MC138 in clinical trials for colorectal cancer, this latest data suggests a broader applicability for the platform across various tumor types where metastasis drives poor patient outcomes.
Comments (0)
No comments yet. Be the first!